Abstract: The potential of academic research to yield new therapeutic opportunities is well understood. However, academic institutions still face significant challenges in accessing the funding, expertise and commercial technology platforms required to progress from novel drug target to robust proof of concept with a candidate therapeutic. Evotec, a life science company focused on research, discovery & development as well as manufacturing of novel precision medicines, has developed its BRIDGE model to provide these translational necessities and works with top academic institutions in Europe and North America to support first in class therapeutic opportunities emerging from their research. BRIDGE partnerships also integrate investment partners who can, together with Evotec, provide seed financing for new spinout companies based on successful projects. The BRIDGE model has to date supported more than 80 projects and has committed capital in excess of € 150m. In this session the BRIDGE model for public-private drug discovery will be explored in more detail, including lessons learned from supporting pre-seed therapeutics projects, the characteristics of an attractive project and advice for academic innovators considering pursuing a translational pathway for their medical discoveries.